XML 29 R43.htm IDEA: XBRL DOCUMENT v2.4.0.6
Commitments and Contingencies (Details) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Future minimum annual payments under operating lease agreements [Abstract]      
2013 $ 2,410    
2014 2,410    
2015 2,470    
2016 2,532    
2017 2,595    
Thereafter 8,182    
Total 20,599    
Rental expense 2,074 3,475 3,544
Adjustments to rental expense 419 63 181
Additional facility charges 2,845 4,033 3,645
Licensing, Service, Supply and Related Party Agreements [Abstract]      
License fees and supply costs 1,170 578 1,266
Consulting Agreements [Abstract]      
Expenses with regard to consulting agreements with scientific specialists 8 27 179
Fair value of options vested included in consulting expenses (in dollars per share)   11 42
Retirement Agreement [Abstract]      
Expenses for termination of employment agreement 1,789    
MTS-Related Party Agreement      
Consulting agreement monthly retainer amount 10    
Success fee 300    
Lonza Sales AG [Member] | Parent Company [Member]
     
Licensing, Service, Supply and Related Party Agreements [Abstract]      
Commitments, paid from inception 909    
Future Commitments 808    
Terms Annual license fee payments, milestones and royalties, as applicable, in respect of oncology and other products.    
Seattle Genetics, Inc. [Member] | PSMA Development Company LLC [Member]
     
Licensing, Service, Supply and Related Party Agreements [Abstract]      
Commitments, paid from inception 4,400    
Future Commitments 13,800    
Terms Milestone and periodic maintenance payments to use ADC technology to link chemotherapeutic agents to monoclonal antibodies that target prostate specific membrane antigen. ADC technology is based in part on technology licensed by SGI from third parties.    
Amgen Fremont, Inc. (formerly Abgenix) [Member] | PSMA Development Company LLC [Member]
     
Licensing, Service, Supply and Related Party Agreements [Abstract]      
Commitments, paid from inception 1,350    
Future Commitments 5,750    
Terms Milestones and royalties to use XenoMouse® technology for generating fully human antibodies to PSMA LLC's PSMA antigen.    
Former Member of PSMA LLC [Member] | PSMA Development Company LLC [Member]
     
Licensing, Service, Supply and Related Party Agreements [Abstract]      
Commitments, paid from inception 241    
Future Commitments $ 52,216    
Terms Annual minimum royalty payments and milestones to use technology related to PSMA.